At the time of further progression, many patients are still in an excellent performance status, but efficacy of further chemotherapy is disappointing with response rate less than 5%, median progression-free survival (mPFS) less than 2 months and mOS around 4 months, and therefore therapy is not recommended outside clinical trials. A new treatment principle was Inhibitors,research,lifescience,medical introduced with the implementation of antibodies against EGFR, even though expression of EGFR does not correlate with outcome. Cetuximab and panitumumab are effective in chemohttp://www.selleckchem.com/products/MG132.html resistant mCRC in patients with KRAS wildtype (KRASwt) tumors, but even more successful in combination with irinotecan with tumor regression in 30-40% of

patients and mOS around 12 months (3). In patients with KRAS mutated (KRASmut) Inhibitors,research,lifescience,medical tumors and in patients with EGFR

resistant KRASwt tumors, there is presently no valuable therapy. Still many patients are in an excellent performance status, and there is an unmet need of further efficient treatment options in these patients. Lapatitinib (Tykerb©) is a tyrosine kinase inhibitor (TKI) of both EGFR (HER1) and HER2. These receptors share a common pathway leading to cell proliferation. Overexpression of EGFR and HER2 is associated Inhibitors,research,lifescience,medical with a worse prognosis in many malignancies, and recent data suggests that upregulation of HER2 may be seen after EGFR inhibition and may be involved in primary and acquired resistance to anti-EGFR therapy (4). It is thus an attractive hypothesis to block both HER1 and HER2 in colorectal

cancer, both as an initial therapeutic strategy, as well as after acquired resistance to prior anti-EGFR therapy. It is therefore surprising that a Inhibitors,research,lifescience,medical previous study showed no efficacy Inhibitors,research,lifescience,medical of lapatinib in colon cancer (5), since responses could have been expected in the 4% HER2 amplified tumors or the 10% of unselected CRC shown to respond to monotherapy EGFR monoclonal antibodies. HER1-2 specific TKI potentially do not block HER1, HER3, HER4 interactions that could be inhibited by HER1 targeting antibodies. Pan-HER TKI inhibitors would potentially address this, but although final results are awaited, phase I data in mCRC with pan HER inhibitors as mono-therapy does not look promising. Other functions of HER1 targeting monoclonal antibodies, such as receptor below internalisation and degradation may be key for the mode of action in colorectal cancer. In this study the authors decided to assign lapatinib another chance by relying on its potential synergy with capecitabine (6). However, the study was terminated early due to the pre-specified stopping criteria (Simons stage 2 design) as no responders were seen, and the authors concluded that “the combination of capecitabine and lapatinib failed to show any clinical activity in heavily pretreated patients with colorectal adenocarcinoma”.